AFAsma Fourati

Asma Fourati

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Asma Fourati has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Expression profile of biomarkers altered in papillary and anaplastic thyroid carcinoma: Contribution of Tunisian patients

    by Asma Fourati, Olfa El Amine, Wided Ben Ayoub, Imen Cherni, Aida Goucha, Michèle Véronique El May, Amor Gamoudi, Ahmed El May


  • Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families

    by Aouatef Riahi, Mohamel el Ghourabi, Asma Fourati, Habiba Chaabouni-Bouhamed

    Background With the increasing request for BRCA1/BRCA2 mutation tests, several risk models have been developed to predict the presence of mutation in these genes; in this study, we have developed an efficient BRCA genetic testing strategy. Method As first step, to identify predictor variables associated with BRCA status, we have undertaken a cumulative mutation analysis including data from three Tunisian studies. Then, we have developed a logistic regression model for predicting the likelihood of harboring a BRCA mutation. Using receiver operating characteristic curves (ROC), an effective evaluation was performed. A total of 92 Tunisian families were included. Overall, 27 women were positive for BRCA1/BRCA2 deleterious mutations. Results Tow recurrent mutations (c.211dupA and c.5266dupC) explained 76 % of BRCA1-related families and three recurrent mutations (c.1310_1313del, c.1542_1547delAAGA and c.7887_7888insA) explained 90 % of BRCA2-related families. Early age at diagnosis of breast cancer, ovarian cancer, bilateral breast cancer were associated with BRCA1, whereas male breast cancer and four or more breast cancer cases in the family were associated with BRCA2. The area under the receiver operating characteristic curve of the risk score was 0.802 (95 % confidence interval = 0.0699–0. 905). Conclusion Logistic regression reported particular profiles related to BRCA germline mutation carriers in our population, as well as an efficient prediction model that may be a useful tool for increasing the cost-effectiveness of genetic testing strategy.


  • Descriptive analysis of molecular subtypes in Tunisian breast cancer

    by Asma Fourati, Hamouda Boussen, Michéle V El May, Aida Goucha, Bouthaina Dabbabi, Amor Gamoudi, Rachida Sfar, Khaled Rahal, Ahmed El May, Mansour Ben Abdallah

    Aim: The objective is to report the correlation between pathology and molecular subtype classifications of breast cancer in Tunisian women.Methods: This retrospective study concerned data of 966 breast cancer cases collected from 2007 to 2009 at Salah Azaiz Institute of Tunis. These cases were classified by an immunohistochemistry test for estrogen and progesterone receptors and human epidermal growth factor receptor 2 (HER2) status in the four molecular subtypes, namely luminal A, luminal B, HER2+ and triple negative. The molecular classifications were correlated with the clinicopathological characteristics of the tumors.Results: Luminal A (50.7% of cases) was the most common subtype, with triple negative subtype 22.5%, luminal B 13.4% and HER2+ 13.4%. Triple negative and HER2+ subtypes were significantly associated with large tumor size (>5 cm, P < 0.001), younger age (P < 0.03) and high grade (P < 0.001). Conversely, there was no correlation with the lymph node status.Conclusion: Our data demonstrated that the luminal A subtype, associated with a favorable prognosis, was the most frequent subtype in the Tunisian population; however the triple negative subtype occurred at a high incidence in Tunisia compared to Western countries. The molecular subtypes are correlated to the tumor size, histological grade and patient's age.


    • 1 April 2009
      • Vol. 38  (2) , 191-6

    Prognostic evaluation of p53, heat shock protein 70, Ki67, and CD34 expression in cancer of the tongue in Tunisia.

    by Asma Fourati, Michèle Véronique El May, Mansour Ben Abdallah, Amor Gamoudi, Nahla Mokni, Aïda Goucha, Hamouda Boussen, Abderrahman Ladgham, Ahmed El May

    Oral tongue cancer remains an aggressive tumour in Tunisia, and patients often present with locally advanced disease, leading to high mortality. The molecular pathway of its tumorigenesis is not yet understood. This study aimed to assess the biologic significance of p53, heat shock protein 70 (Hsp70), Ki67, and CD34 and their influence on survival in patients with tongue cancer. Archival tissues from 68 patients with squamous cell carcinoma of the tongue were examined for p53, Hsp70, Ki67, and CD34 by immunohistochemistry and correlated with 5-year survival. p53 and Ki-67 were detected in 55% and 77% of tumours, respectively; a significant association between p53 and Ki67 expression was found (p = .038). Forty-seven percent of cases of tongue cancer expressed Hsp70, and only 9% of tumours expressed CD34 angiogenic factor. No significant correlation was noted between survival and expression of p53, Hsp70, Ki67, and CD34 in patients. None of the markers p53, Hsp70, Ki67, and CD34 demonstrated prognostic significance for 5-year survival in patients with squamous cell carcinoma of the tongue.


    • 1 February 2007
      • Vol. 85  (2) , 105-8

    Correlation between P53 expression and CD34 angiogenic factor in Tunisian breast cancer.

    by Asma Fourati, Fathi Khomsi, Michele V El May, Khaled Rahal, Amor Gamoudi, Hamouda Boussen, Mansour Ben Abdallah, Ahmed El May

    Angiogenesis is a significant prognostic factor in breast cancer, but the factors that control angiogenesis in vivo are not well defined. The purpose of this study was to investigate P53 expression in breast cancer and to examine the relationship between P53 overexpression and the degree of angiogenesis. A total of 52 paraffin-embedded tumors were evaluated immunohistochemically for expression of P53 and CD34 angiogenesis factor. The majority of P53 positive cases (82%) demonstrated high level of microvessel density (MVD); 18% demonstrated no CD 34 expression. In contrast there was no variation of CD34 expression among P53 negative tumors. This data suggests that microvessel density is promoted by P53 overexpression in breast cancer, and is correlated with high histologic grade.